The case for genotypic data

In this video interview, Silvia Argimón, Senior technical advisor at the World Health Organization (WHO), talks to Conor to discuss her work on antimicrobial resistance (AMR) and genomic surveillance

She explains her role in supporting the International Pathogen Surveillance Network to enhance access to genomic surveillance of drug-resistant pathogens. Silvia emphasizes the importance of combining genomic data with antimicrobial susceptibility testing and epidemiological information to understand the spread of AMR and to develop targeted interventions. She highlights the use of genomics in clinical settings, such as in tuberculosis (TB), where genotypic predictions can accelerate treatment decisions, and mentions efforts by WHO to expand similar genomic catalogues for other pathogens.

Silvia further discusses the advantages of genomic surveillance for public health, noting that genomic data can identify all known resistance determinants and their potential for spread across species. She underscores the importance of community involvement in creating standards for data collection and analysis to ensure the accuracy of AMR predictions from genomic data.

Silvia also addresses the need for equitable genomic surveillance capacity globally, stressing the role of initiatives like the International Pathogen Surveillance Network and accessible online courses in overcoming barriers and building capacity in countries.

Silvia mentions the importance of community involvement in developing standards and methods for genomic surveillance. What are some potential challenges in achieving this, and how might they be overcome in your opinion?